The discovery of specific small-molecule HuR antagonists, such as KH3 and KH39, which selectively disrupt the HuR–ARE interaction and inhibit downstream protein expression, has shown substantial effectiveness in the progression of CKD and cardiovascular disease (CVD) in various animal models [10,11,13]. This evidence concerns the gene ELAVL1 and cardiovascular disorder.